*.*.44.54
药智数据企业版
量身打造,体验升级
立即前往
VIP试用申请
登录 注册
当前位置: 首页 > 美国溶出度方法 反馈纠错 帮助中心
药智数据企业版注册数据库:增设了"联合申报"、"临床试验默认许可日期"等搜索条件,让搜索页面纬度更加全面,还有热点搜索和高级条件组合检索等检索功能 等你来体验!
-
药品名称 剂型 USP 溶出方法 转速(转/min) 溶出介质 容积 推荐采样时间 更新时间 查看详情
Voxelotor Tablet, for Suspension II (Paddle) 75 50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS) 900 5, 10, 15, 20 and 30 2022-07-28 查看
Voxelotor Tablet II (Paddle) 75 50 mM phosphate buffer (pH 6.8) with 2% sodium lauryl sulfate (SLS) 900 5, 10, 20, 30 and 45 2022-07-28 查看
Apalutamide Tablet II (Paddle) 75 0.25% sodium lauryl sulfate (SLS) in 0.05 M Sodium Phosphate Buffer, pH 4.5 900 5, 10, 15, 20, 30, and 45 2022-07-28 查看
Edaravone Suspension II (Paddle) 75 pH 4.0 Acetate Buffer 900 5, 10, 15, 20 and 30 2022-07-28 查看
Posaconazole For Suspension (Delayed Release) II (Paddle) 75 Acid stage: 0.01 N HCl; Buffer stage: pH 6.8 Phosphate buffer with 1.3% Tween 80; Acid stage: 750 mL; Buffer stage: 1000 mL Acid stage: 120; Buffer stage: 5, 10, 15, 20, 30 and 45 2022-07-07 查看
Bupivacaine Solution (Extended Release), Infiltration II (Paddle) 50 0.025 M Sodium Phosphate Buffer with 0.03% Sodium Dodecyl Sulfate (SDS), pH 7.4 900 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours 2022-07-07 查看
Bismuth Subsalicylate (BiSub)/Metronidazole (Met)/Tetracycline HCl (Tet) BiSub: Tablet (Chewable) /Met:Tablet /Tet: Capsule II (Paddle) 50 BiSub: 0.1 N HCl /Met: Refer to USP /Tet: Refer to FDA's Dissolution Guidance, 2018 900 5, 10, 15, 20 and 30 2022-07-07 查看
Selpercatinib Capsule II (Paddle) 75 0.1N HCl 900 5, 10, 15, 20 and 30 2022-07-07 查看
Exenatide Synthetic (2 mg) For Suspension, Extended Release Develop a method to characterize in vitro release 2022-07-07 查看
Nifurtimox Tablet II (Paddle) 100 Acetate Buffer, pH 4.5 with 1.0 % Sodium Dodecyl Sulfate (SDS) (for 30 mg strength) and 1.5 % SDS (for 120 mg strength) 900 10, 20, 30, 60 and 75 2022-07-07 查看
Selumetinib Capsule II (Paddle) with sinker 75 Sodium Phosphate Buffer, pH 6.5, with 0.5% Polysorbate 80 1000 10, 20, 30, 45 and 60 2022-07-07 查看
Hydroxyurea Tablet Refer to FDA's Dissolution Guidance, 2018 2022-07-07 查看
Darunavir(Drv)/Cobicistat (Cobi)/Emtricitabine (Emt)/Tenofovir Alafenamide Fumarate (Taf) Tablet II (Paddle) 75 Drv: 0.05 M Sodium Phosphate Buffer, pH 3.0, 2% Tween 20; For Cobi, Emt and Taf: Citrate Phosphate Buffer, pH 4.2 900 Drv: 10, 15, 20, 30 and 45; For Cobi, Emt and Taf: 5, 10, 15, 20 and 30 2022-07-07 查看
Cabotegravir Sodium Tablet II (Paddle) 60 0.01N HCl with 0.2% cetyltrimethylammonium bromide (CTAB) 1000 5, 10, 15, 20, 25 and 30 2022-07-07 查看
Ranolazine Granules (Extended Release) II (Paddle) 50 0.1 N HCl 900 0.5, 1, 2, 3, 4, 6 and 8 hours 2022-07-07 查看
Cedazuridine/Decitabine Tablet II (Paddle) 75 50 mM phosphate buffer, pH 6.8 900 5, 10, 15 and 30 2022-07-07 查看
Deferiprone (1 GM) Tablet I (Basket) 100 Acidic Stage: 0.1 N HCl, Buffer Stage: 0.05 M Phosphate buffer, pH 6.8. Acid Stage: 2 hours; Buffer Stage: 1, 2, 3 and 4 hours 2022-07-07 查看
Relugolix Tablet II (Paddle) 50 50 mM Citrate Buffer, pH 5.5 900 5, 10, 15, 20 and 30 2022-07-07 查看
Chlorhexidine Gluconate Tablet (Dental) Develop a method to characterize in vitro release 2022-07-07 查看
Exenatide Synthetic (2 mg/0.85 mL) Suspension, Extended Release Develop a method to characterize in vitro release 2022-07-07 查看